Treatment with the clinical candidate, obeticholic acid reversed the hepatic steatosis phenotype and transcriptomic analysis confirmed the selective activation of FXR target genes including upregulation of FGF19 and PLIN1 and downregulation of SLC51B and CYP7A1 genes by OCA. This evidence concerns the gene SLC51B and Hepatic steatosis.